Degenerative Disc Disease Pipeline Review – H1 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Degenerative Disc Disease – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease – Pipeline Review, H1 2020, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.

Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 3, 4, 1 and 1 respectively.

Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Degenerative Disc Disease – Overview
• Degenerative Disc Disease – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Products under Development by Companies
• Degenerative Disc Disease – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Degenerative Disc Disease – Companies Involved in Therapeutics Development
• Amplicore Inc
• AnGes Inc
• Bone Therapeutics SA
• CHA Bio & Diostech Co Ltd
• DiscGenics Inc
• Histogen Inc
• Kolon TissueGene Inc
• Locate Bio Ltd
• Notogen Inc
• Spinalcyte Llc
• Techfields Pharma Co Ltd
• U.S. Stem Cell Inc
• Yuhan Corp
• Degenerative Disc Disease – Drug Profiles
• AdipoCell – Drug Profile
• ALLOB – Drug Profile
• AM-2101 – Drug Profile
• Degenerative Disc Disease – Dormant Projects
• Degenerative Disc Disease – Product Development Milestones
• Featured News & Press Releases
• Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jwpg47

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900